Creative Medical Technology Holdings (CELZ) Stock Analysis & AI Equity Report
Creative Medical Technology Holdings (CELZ) overview
Creative Medical Technology Holdings (CELZ) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 0.0m and operating profit of USD -6.1m; the year-end share price was 1.96 USD and market capitalisation was USD 7.2m. Creative Medical Technology Holdings is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Creative Medical Technology Holdings's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Creative Medical Technology Holdings
Creative Medical Technology Holdings is a commercial-stage biotechnology company developing regenerative therapies in immunotherapy, endocrinology, urology, neurology, and orthopedics. Its programs include therapies based on reprogrammed immune cells and other stem-cell approaches for conditions such as erectile dysfunction, type 1 diabetes, and chronic lower back pain. It also develops cell-line and induced pluripotent stem-cell programs through subsidiaries.
Generate the Creative Medical Technology Holdings report
Creative Medical Technology Holdings is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Creative Medical Technology Holdings and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Creative Medical Technology Holdings
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.